Oncolytics Biotech stock: GOBLET data show durable anal-cancer responses
Published on 10/30/2026 at 03:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGOBLET-Daten und nächste Entwicklungsschritte
- Die Daten stammen aus Cohort 4 der Phase-1/2-GOBLET-Studie bei zuvor behandelten Patienten mit Plattenepithelkarzinom des Analkanals.
- Das mediane Gesamtüberleben war zum Datenzeitpunkt noch nicht erreicht.
- Oncolytics sieht nach Gesprächen mit der FDA einen möglichen Entwicklungspfad bis zur Registrierung, vorbehaltlich weiterer Daten und regulatorischer Zustimmung.
On October 27, 2026, Oncolytics Biotech reported updated clinical data from Cohort 4 of its phase 1/2 GOBLET study. The release, published by GlobeNewswire, concerns pelareorep combined with atezolizumab in patients with second-line or later squamous cell anal cancer.
Durability remains the central data point
Oncolytics said the median duration of response was approximately 15 months. The company compared that result with a historical 9.5-month duration reported for retifanlimab monotherapy in a similar population. That is a cross-trial historical comparison rather than evidence from a randomized head-to-head study.
All patients who responded to treatment survived beyond 12 months, according to the company, with multiple responders surviving beyond 24 months. Median overall survival had not yet been reached. The release did not present these responder-survival figures as a substitute for a controlled overall-survival analysis.
Regulatory ambitions still depend on follow-up
Oncolytics said recent FDA interactions and Fast Track designation support its plans to explore registrational development in advanced squamous cell anal cancer. The company also pointed to possible expansion into other HPV-associated tumors, including head and neck cancer.
For investors, the update strengthens the durability narrative around pelareorep, but the development remains clinical-stage. Regulatory agreement, trial execution, additional follow-up and future study design remain important uncertainties before any approval conclusion can be drawn.
Oncolytics Biotech at a glance
- Company: Oncolytics Biotech Inc.
- ISIN: CA6823108759
- Ticker: ONCY
- Primary market: Nasdaq
- Development focus: Pelareorep-based immunotherapy for gastrointestinal cancers
The broader U.S. market backdrop is represented by the S&P 500.
